Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...

The drug givinostat - used for Duchenne Muscular Dystrophy management - remains unavailable to boys and young men who can no ...

Managing the transition to mobility aids is a pivotal part of life with DMD. Discover expert strategies for maintaining independence through physical therapy, adaptive technology, and home ...

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.

Learn how to exercise safely with Duchenne muscular dystrophy, for your flexibility, mobility, and overall health, without damaging your muscles.

The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...

This study was carried out on 9 patients with myotonic dystrophy and 8 with slowly progressive nonmyotonic muscular dystrophy admitted to the Neurology Service at Duke University Hospital and the ...

DR. JULIA BELL has contributed a useful monograph on muscular dystrophy in man to “The Treasury of Human Inheritance” series. Clinical and genetical data from more than 1,300 individuals exhibiting ...